New insider activity at Alnylam Pharma ( (ALNY) ) has taken place on March 6, 2025.
In recent transactions involving Alnylam Pharma stock, CEO Yvonne Greenstreet sold 3,877 shares, amounting to $945,164. EVP & CFO Jeffrey V. Poulton parted with 1,264 shares, totaling $308,140. CSO & EVP, Head of Research Fitzgerald Kevin Joseph sold 740 shares for $180,401. CMO & EVP Dev & Med Affairs Pushkal Garg sold 776 shares, valued at $189,183. Lastly, EVP & CCO Tolga Tanguler sold 471 shares, worth $114,820.
Recent Updates on ALNY stock
In the last 24 hours, Alnylam Pharmaceuticals has seen mixed analyst reactions following its recent earnings call and financial performance report. Canaccord raised its price target slightly, citing the company’s focus on the upcoming Amvuttra label expansion in ATTR-CM and potential price adjustments as key factors. Meanwhile, Scotiabank lowered its price target due to anticipated challenges despite being encouraged by consistent revenue growth and the company’s strategic execution on clinical and regulatory fronts. Alnylam’s earnings call highlighted a strong 33% growth in net product revenues, driven by the TTR franchise and advancements in its R&D pipeline, although minor setbacks were noted in its rare franchise. The company projects continued growth and profitability, with a focus on expanding its RNAi platform and achieving significant revenue growth in 2025.
More about Alnylam Pharma
YTD Price Performance: 3.99%
Average Trading Volume: 693,311
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $31.45B